Overview

Effects of Ezetimibe Add-On to Statin Therapy on Adipokine Production in Obese and Metabolic Syndrome Patients With Atherosclerosis

Status:
Completed

Trial end date:
2009-04-01

Target enrollment:

Participant gender:

Summary

The purpose of this study is to investigate the effects of adding ezetimibe to statin therapy on levels of inflammatory markers and adipokines in patients with atherosclerosis disease and features of the metabolic syndrome,whose LDL-c remains above target (> 2.0 mmol/L) despite statin monotherapy. We hypothesize that the addition of Ezetimibe (10mg per day for 12 weeks) to ongoing statin therapy in patients with atherosclerosis and features of the metabolic syndrome will favourably modify levels of inflammatory biomarkers and adipokines.

Phase:

N/A

Details

Lead Sponsor:

Canadian Cardiovascular Research Network
Canadian Collaborative Research Network

Collaborator:

Schering-Plough

Treatments:

Ezetimibe